• Hanfei Guo, Wenqian Li, Ye Guo, Naifei Chen, and Jiuwei Cui.
• Cancer Center, The First Hospital of Jilin University, Changchun, Jilin 130021, China.
• Chin. Med. J. 2024 Jan 20; 137 (2): 130139130-139.

AbstractSmall cell lung cancer (SCLC) is a highly malignant tumor with a very poor prognosis; therefore, more effective treatments are urgently needed for patients afflicted with the disease. In recent years, emerging molecular classifications based on key transcription factors of SCLC have provided more information on the tumor pathophysiology, metastasis, immune microenvironment, and acquired therapeutic resistance and reflected the intertumoral heterogeneity of the various SCLC phenotypes. Additionally, advances in genomics and single-cell sequencing analysis have further revealed the high intratumoral heterogeneity and plasticity of the disease. Herein, we review and summarize these recent lines of evidence and discuss the possible pathogenesis of SCLC.Copyright © 2024 The Chinese Medical Association, produced by Wolters Kluwer, Inc. under the CC-BY-NC-ND license.

17 keywords...

hide…